Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017336 | 0.87 | PRMT6 (0.53) | PRMT6CARM1SLC6A2SLC6A4CCR3 | |
| SCHEMBL3318445 | 0.84 | PRMT6 (0.54) | PRMT6CARM1TMEM97SLC6A2SLC6A4 | |
| SCHEMBL3322011 | 0.83 | PRMT6 (0.49) | PRMT6CARM1 | |
| SCHEMBL3319043 | 0.80 | PRMT6 (0.52) | PRMT6CARM1TMEM97SLC6A2SLC6A4 | |
| SCHEMBL3321544 | 0.79 | PRMT6 (0.54) | PRMT6CARM1TMEM97SLC6A2SLC6A4 | |
| SCHEMBL3321799 | 0.78 | PRMT6 (0.50) | PRMT6CARM1SLC6A2SLC6A4CCR3 | |
| SCHEMBL3320600 | 0.78 | PRMT6 (0.49) | PRMT6CARM1TMEM97SLC6A2SLC6A4 | |
| SCHEMBL3320786 | 0.78 | PRMT6 (0.49) | PRMT6CARM1TMEM97SLC6A2SLC6A4 | |
| SCHEMBL3630106 | 0.76 | SLC6A2 (0.54) | PRMT6CARM1SLC6A2SLC6A4CCR3 | |
| SCHEMBL3322192 | 0.74 | CARM1 (0.56) | PRMT6CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| EP-2155748-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008144268-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, AGTR1, AGTR2 | PRMT6 2129/4885CARM1 3295/4885TMEM97 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.